【ChiCTR1900021995】Retinal Nerve Fiber Layer Optical Texture Signature as a Novel Biomarker for Detection of Glaucoma Progression
ChiCTR1900021995
正在进行
/
/
/
2019-03-19
/
/
青光眼
Retinal Nerve Fiber Layer Optical Texture Signature as a Novel Biomarker for Detection of Glaucoma Progression
Retinal Nerve Fiber Layer Optical Texture Signature as a Novel Biomarker for Detection of Glaucoma Progression
1. To compare the hazard ratios for development of visual field progression upon detection of progressive decline in retinal nerve fiber layer (RNFL) optical texture signature versus upon detection of progressive RNFL thinning 2. To compare the survival distributions between eyes with progressive RNFL thinning and eyes with progressive decline in RNFL optical texture signature 3. To determine the specificities of Trend-based Progression Analysis (TPA) for detection of progressive decline in RNFL optical texture signature and progressive RNFL thinning 4. To measure rates of change of VF mean deviation between eyes with and without progressive decline in RNFL thickness/optical texture signature 5. To measure age-related rates of change of RNFL thickness/optical texture signature 6. To compare the sensitivity and specificity for detection of glaucoma between ROTA and conventional OCT analysis
析因分组（即根据危险因素或暴露因素分组）
其它
N/A
N/A
General Research Fund 2018-19
/
539
/
2019-04-01
2023-06-30
/
The inclusion criteria are: age ≥18 years; best corrected visual acuity (VA) ≥20/40.；
请登录查看The exclusion criteria are: IOP >30mmHg; only one eye with functional vision; inability to perform reliable VF; pathological myopia (eyes with axial length≥26mm with lacquer cracks and chorioretinal atrophy); suboptimal quality of OCT images; previous intraocular surgery other than uncomplicated cataract extraction; and diabetic retinopathy/ maculopathy.；
请登录查看Research Grant Council, University Grants Committee
/
Research Grant Council, University Grants Committee的其他临床试验
香港中文大學眼科學與視覺科學系的其他临床试验
最新临床资讯
-
诺华：CFB抑制剂终止狼疮肾炎二期临床
医药笔记2026-10-17
-
泽安生物医药：实体瘤MCE启动一期临床
医药笔记2026-10-17
-
药明康德2026-10-17
-
沃森生物2026-10-16
-
罕见病信息网2026-10-16
-
武警特色医学中心2026-10-16
-
生物经纬2026-10-16
-
良医汇肿瘤资讯2026-10-16
-
BioMed科技2026-10-16
-
蒲公英资讯2026-10-16
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-10-26
-
2026-10-25
-
2026-10-25
-
摩熵咨询 33 49
-
摩熵咨询 20 3
-
摩熵咨询 20 10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
-
颁布机构：国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构：国家药品监督管理局 2026-09-10
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-10-23
-
2026-10-23
-
2026-10-21
-
摩熵咨询 35 83
-
摩熵咨询 28 70
-
摩熵咨询 34 47
-
颁布机构：国家药品监督管理局 2026-10-19
-
颁布机构：国家市场监督管理总局 2026-10-16
-
颁布机构：国家市场监督管理总局 2026-09-30